scholarly journals Overall survival and tumor recurrence after surgical resection for primary malignant chest wall tumors: a single-center, single-surgeon experience

2019 ◽  
Vol 27 (2) ◽  
pp. 230949901983829 ◽  
Author(s):  
Aalap C Shah ◽  
Kazimierz W Komperda ◽  
Arun A Mavanur ◽  
Steven W Thorpe ◽  
Kurt R Weiss ◽  
...  
Keyword(s):  
Overall Survival ◽  
Chest Wall ◽  
Surgical Resection ◽  
Tumor Recurrence ◽  
Single Center ◽  
Chest Wall Tumors ◽  
Surgeon Experience

scholarly journals Histologic Types of Chest Wall Tumors—Nine Years’ Single Center Experience

2014 ◽  
Vol 04 (01) ◽  
pp. 13-19
Author(s):  
Zohreh Mohammadtaheri ◽  
Atosa Dorudinia ◽  
Abolghasem Daneshvar ◽  
Pegah Akhavan Azar ◽  
Foruzan Mohammadi
Keyword(s):  
Chest Wall ◽  
Single Center ◽  
Chest Wall Tumors ◽  
Single Center Experience ◽  
Histologic Types

scholarly journals Multidisciplinary approach to chest wall resection and reconstruction for chest wall tumors, a single center experience

2017 ◽  
Vol 9 (12) ◽  
pp. 5093-5100 ◽  
Author(s):  
Elisa Scarnecchia ◽  
Valeria Liparulo ◽  
Alessandra Pica ◽  
Giuseppe Guarro ◽  
Carmine Alfano ◽  
...  
Keyword(s):  
Chest Wall ◽  
Multidisciplinary Approach ◽  
Chest Wall Resection ◽  
Single Center ◽  
Chest Wall Tumors ◽  
Single Center Experience

Surgical Resection of Secondary Chest Wall Tumors

2005 ◽  
Vol 53 (4) ◽  
pp. 234-239 ◽  
Author(s):  
J. Pfannschmidt ◽  
P. Geisbüsch ◽  
T. Muley ◽  
H. Hoffmann ◽  
H. Dienemann
Keyword(s):  
Chest Wall ◽  
Surgical Resection ◽  
Chest Wall Tumors

scholarly journals Stem Cell Delivery of Oncolytic Adenovirus DNX-2401 Following Surgical Resection for the Treatment of Glioblastoma in a Murine Model

Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Sricharan Gopakumar ◽  
Joy Gumin ◽  
Marc Daou ◽  
Daniel Ledbetter ◽  
Brittany Parker Kerrigan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Treatment Group ◽  
Tumor Cells ◽  
Surgical Resection ◽  
Tumor Recurrence ◽  
Residual Disease ◽  
Tumor Resection ◽  
In Vivo Studies ◽  
Resection Cavity ◽  
Stem Cell Delivery

Abstract INTRODUCTION Current treatments for glioblastoma (GBM) are minimally effective and the prognosis for patients is uniformly poor despite multimodal therapy. While prior studies have examined intratumoral injection of oncolytic virus DNX-2401 into recurrent tumor, the potential of DNX-2401 delivered into the surgical resection cavity using tumor-tropic human mesenchymal stem cells (MSCs) has not been evaluated. We hypothesize that using a fibrin scaffold for transplanting MSCs loaded with DNX-2401 (MSCs-DNX-2401) into the resection cavity will improve MSC and viral delivery, kill residual tumor cells, decrease GBM recurrence, and improve overall survival. METHODS MSCs-DNX-2401 were either seeded in fibrin or suspended in PBS and placed in the upper wells of a transwell with U87 tumor cells plated below. After 1 wk, U87 cells were counted to compare rates of cellular killing to evaluate release of DNX-2401 from fibrin-seeded MSCs. U87 tumor cells were then transduced with mCherry-Luciferase and implanted in 20 mice. Fluorescence-guided surgical resection of glioma xenografts was performed on day 10. Either MSCs (control) or MSCs-DNX-2401 (treatment) were seeded in fibrin and implanted in the resection cavity. Postoperative bioluminescence imaging was used to evaluate extent of residual disease and weekly serial imaging was used to monitor tumor recurrence in each group. RESULTS Transwell experiments demonstrate significant cytotoxic killing of U87 tumor cells with MSCs-DNX-2401 seeded in fibrin having comparable oncolytic activity to MSC-DNX-2401 without fibrin. In vivo studies show four mice in the treatment group (40%) demonstrating complete responses to delivery of MSCs-DNX-2401 using fibrin. Kaplan-Meier survival analysis demonstrates survival benefit with prolonged median and overall survival in the treatment group (P < .05). CONCLUSION This translational study validates the overall treatment paradigm for delivering oncolytic virotherapy into the tumor resection cavity using MSCs seeded in fibrin to decrease tumor recurrence and prolong overall survival. This project represents an important preliminary step for eventual application of this technology in human patients.

Induction chemoradiation is associated with improved survival in chest wall invasion lung cancer

2019 ◽  
Vol 105 (4) ◽  
pp. 331-337 ◽  
Author(s):  
Juan A Muñoz-Largacha ◽  
Sowmya R Rao ◽  
Laurence H Brinckerhoff ◽  
Benedict D Daly ◽  
Hiran C Fernando ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Chest Wall ◽  
Surgical Resection ◽  
Clinical Stage ◽  
Disease Recurrence ◽  
High Dose ◽  
Chest Wall Invasion ◽  
Superior Sulcus ◽  
Wall Invasion

Objective: To determine if induction chemotherapy with concurrent high-dose radiation followed by resection is associated with improved survival in patients with nonsuperior sulcus lung cancer with chest wall invasion. Methods: We performed a retrospective review of clinical T3 (chest wall invasion) N0/N1 patients with non-small cell lung cancer who underwent surgical resection between January 1, 1992, and January 31, 2017. Exclusion criteria included superior sulcus tumors and resection performed for palliation/recurrence. Patients undergoing induction chemoradiation followed by surgical resection were compared to those undergoing resection first or those receiving induction radiation followed by resection. Overall survival was calculated using the Kaplan-Meier method. Results: Thirty-four patients were included in the analysis, with 5-year overall survival (OS) of 30%. By clinical stage, 31 (91%) were IIB (T3N0) and 3 (9%) were IIIA (T3N1). Sixteen patients (47%) received induction chemoradiation before surgery. Of the remaining 18 patients, 5 (15%) received induction radiation followed by surgery, and 13 (38%) underwent surgery as the first treatment. Three patients belonging to the group not receiving induction chemoradiation died within 30 days after surgery and were excluded from survival analysis. In the remaining 31 patients, induction chemoradiation was associated with improved 5-year OS (53% for induction chemoradiation vs 7% for others; P<0.01). Disease recurrence was evident in 9 cases, 2 (12.5%) in the induction chemoradiation group and 7 (46.6%) in the others (median disease-free time 103.0 months for induction chemoradiation group vs 8.0 months for others; P<0.01). Conclusion: In patients with nonsuperior sulcus lung cancer with chest wall invasion, induction chemoradiation therapy followed by resection is associated with improved OS.

scholarly journals Management of chest wall tumors: a single-center experience

2017 ◽  
Vol 2 (2) ◽  
pp. 46
Author(s):  
Tarık Yağcı ◽  
Ahmet Üçvet ◽  
Ezgi Çimen Güvenç ◽  
Banu Yoldaş ◽  
Soner Gürsoy
Keyword(s):  
Chest Wall ◽  
Single Center ◽  
Chest Wall Tumors ◽  
Single Center Experience

scholarly journals Primary Small Cell Carcinoma in Nasal Cavity and Paranasal Sinuses: 15 Cases From a Single Center

2021 ◽  
pp. 014556132110498
Author(s):  
Jian Wang ◽  
Yingying Fan ◽  
Xiao-dong Chen ◽  
Tao Xue ◽  
Fu-quan Chen
Keyword(s):  
Overall Survival ◽  
Nasal Cavity ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Tumor Recurrence ◽  
Small Cell ◽  
Comprehensive Treatment ◽  
Single Center

Small cell carcinoma (SCC) in the nasal cavity and sinuses is extremely rare. The clinical data of 15 patients with primary SCC in nasal cavity and sinuses were analyzed retrospectively. All patients were treated with surgery, radiotherapy, and chemotherapy. Of the 15 patients, 2 patients are alive for more than 6 years, and 5 patients died after the median follow-up period (11 months). Most of our patients represent the later stage (73% presented at stage III or IV) and had surgery combined with radiotherapy and chemotherapy; however, nearly half of patients have tumor recurrence and/or distant metastasis. SCC of nasal cavity and sinuses often invades surrounding tissues, and the long-term curative rate is generally low. Early diagnosis and comprehensive treatment are key to improve survival. Although the overall survival time of SCC is not optimistic, it is still recommended that patients take comprehensive treatment.

Sign in / Sign up

Export Citation Format

Share Document